about
The orphan receptor NOR1 participates in isoprenaline-induced cardiac hypertrophy by regulating PARP-1Tanshinone IIA suppresses cholesterol accumulation in human macrophages: role of heme oxygenase-1.Cyclovirobuxine D induces autophagy-associated cell death via the Akt/mTOR pathway in MCF-7 human breast cancer cells.The poly(ADP-ribosyl)ation of FoxO3 mediated by PARP1 participates in isoproterenol-induced cardiac hypertrophy.STAT3 Suppression Is Involved in the Protective Effect of SIRT6 Against Cardiomyocyte Hypertrophy.α-Enolase plays a catalytically independent role in doxorubicin-induced cardiomyocyte apoptosis and mitochondrial dysfunction.PARP-2 knockdown protects cardiomyocytes from hypertrophy via activation of SIRT1.COX-2 is involved in ET-1-induced hypertrophy of neonatal rat cardiomyocytes: role of NFATc3.Mitochondrial binding of α-enolase stabilizes mitochondrial membrane: its role in doxorubicin-induced cardiomyocyte apoptosis.PARP1 induces cardiac fibrosis by mediating mTOR activity.Upregulation of α-enolase protects cardiomyocytes from phenylephrine-induced hypertrophy.G3BP2 is involved in isoproterenol-induced cardiac hypertrophy through activating the NF-κB signaling pathway.Sensitive electrochemical aptamer cytosensor for highly specific detection of cancer cells based on the hybrid nanoelectrocatalysts and enzyme for signal amplification.A repeatable assembling and disassembling electrochemical aptamer cytosensor for ultrasensitive and highly selective detection of human liver cancer cells.SIRT6 suppresses isoproterenol-induced cardiac hypertrophy through activation of autophagy.PARP1 interacts with STAT3 and retains active phosphorylated-STAT3 in nucleus during pathological myocardial hypertrophy.sFRP1 has a biphasic effect on doxorubicin-induced cardiotoxicity in a cellular location-dependent manner in NRCMs and RatsSIRT1 represses PKC-zeta activity via regulating interplay of acetylation and phosphorylation in cardiac hypertrophyDkk1 exacerbates doxorubicin-induced cardiotoxicity by inhibiting the Wnt/β-catenin signaling pathwayPARP1 interacts with HMGB1 and promotes its nuclear export in pathological myocardial hypertrophyJMJD3 inhibition protects against isoproterenol-induced cardiac hypertrophy by suppressing β-MHC expressionProtocatechuic aldehyde protects against isoproterenol-induced cardiac hypertrophy via inhibition of the JAK2/STAT3 signaling pathwayCompetitive electrochemical platform for ultrasensitive cytosensing of liver cancer cells by using nanotetrahedra structure with rolling circle amplificationVps4A mediates the localization and exosome release of β-catenin to inhibit epithelial-mesenchymal transition in hepatocellular carcinoma[Effects of short-chain acyl-CoA dehydrogenase on human umbilical vein endothelial cell apoptosis][Change of short-chain acyl-CoA dehydrogenase in heart failure after myocardial infarction in rats and the intervention of aerobic exercise]Chrysophanol protects against doxorubicin-induced cardiotoxicity by suppressing cellular PARylationSESN2 protects against doxorubicin-induced cardiomyopathy via rescuing mitophagy and improving mitochondrial functionElectrochemical dual-aptamer-based biosensor for nonenzymatic detection of cardiac troponin I by nanohybrid electrocatalysts labeling combined with DNA nanotetrahedron structureAptamer-based electrochemical cytosensors for tumor cell detection in cancer diagnosis: A reviewChrysophanol attenuated isoproterenol-induced cardiac hypertrophy by inhibiting Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway
P50
Q28581148-5B0AE9BE-E3A8-4313-B4A3-29C3B8E56331Q37457211-9A4BA427-D8E0-4B40-A43D-C938063C917BQ39001729-B82494EF-8196-459A-8F0A-0AACEC4E7627Q39338239-7BC1CC8C-F9C7-4B06-BDF1-E02BD265B0ECQ40695454-C38F5195-6F6C-4BB4-B5DF-99F3B09DAA4DQ42178452-A3BE5E47-919A-4868-ACF2-BB30D995E9B0Q44177617-04376A49-D281-4565-83B6-07FBC8B0EC30Q45371729-C1031609-780A-4684-9444-D3F696C17600Q46716119-5F6A37ED-31D9-4E6E-8B12-2EDE49322D0DQ47218656-24A81D52-177B-4F76-AD2F-88FF83F7356CQ47802537-79E59928-7315-4A2B-85AC-1FF585E263DFQ47941940-2B0F0482-80D7-47B0-AB27-2D34C73478BAQ50939872-A8216D21-7C2D-4CA4-85EA-60211C306918Q50949911-D05DDBA9-8B3C-41ED-8D4D-CD9451F3D67BQ52669826-6040E9F8-3D16-44A3-826C-77B1D353552FQ52675853-EEB98755-0CE1-4604-BB18-5DACFF1E655CQ58093002-404959A1-43A1-4F22-972E-111E8370F6F1Q58555570-E8B75087-874A-4B8C-AFF9-79B6D29C052DQ64374700-C7EACCBA-2E72-4281-8696-E9DAED41E3D8Q64376823-961C9F43-80CD-480E-A08F-F31D3A5C375BQ88647807-E5892AE4-DDA0-4668-92AD-8C7FA5C7B008Q91071733-788323D3-859A-40B2-B6E2-CE4C8D8BE30EQ91127668-14980DDD-E96C-4EAC-B6C6-1DDFE052C771Q91791939-333E9D83-9539-41F5-A866-5460A9B645B4Q91965537-E59CE939-0061-4C95-8664-F8C3E51AF196Q92081034-8C1720C2-E867-4A47-8761-6476A376FB7CQ92435741-AD2E58FD-AB24-4256-9C22-A7AC83A0E1E8Q92752474-0EF0667A-C8E2-41C5-8601-004C732988B5Q92897995-77F12668-9CF3-4028-A0EE-E9F3BC735F94Q93032569-14BD6D67-81E4-4A7D-9599-C8EF957BEBC9Q93051415-209A230B-7D8D-47DB-A9E2-00B114BF594F
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jing Lu
@ast
Jing Lu
@en
Jing Lu
@es
Jing Lu
@nl
Jing Lu
@sl
type
label
Jing Lu
@ast
Jing Lu
@en
Jing Lu
@es
Jing Lu
@nl
Jing Lu
@sl
altLabel
Lu Jing
@en
prefLabel
Jing Lu
@ast
Jing Lu
@en
Jing Lu
@es
Jing Lu
@nl
Jing Lu
@sl
P1053
N-1190-2017
P106
P1153
56200658700
P2038
P214
115152079222607112339
P31
P3829
P496
0000-0001-5766-2775
P569
2000-01-01T00:00:00Z